MEGESTROL ACETATE IMPURITY B
Non-small Cell Lung Cancer
Hunan Province Tumor HospitalSmall moleculePhase 3Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 59/ 100
Competitive context
216 Active assets in the Non-small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Icotinib The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | BBB |
Endostar Henan Cancer Hospital | Phase 4 | BB |
Gefetinib Brigham and Women's Hospital | Phase 4 | BB |
LENVATINIB Sun Yat-sen University | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
MEGESTROL ACETATE IMPURITY B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →